ReviewJournal of viral hepatitis2018
Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era.
Review in Journal of viral hepatitis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.International journal of environmental research and public health · 2020Pooled it
- Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Community-based interventions for hepatitis C virus elimination among people who use drugs in Shanghai, China.Harm reduction journal · 2026Article
- Epidemiology and control of hepatitis C virus infection in Brunei Darussalam: a retrospective cohort study.IJID regions · 2026Article
- Impact of Risk Heterogeneity on the Feasibility of Hepatitis C Elimination Among People Who Inject Drugs: A Modelling Study.Journal of viral hepatitis · 2025Article
- Review
- Addressing viral hepatitis C reinfections in a low-threshold programme for people who inject drugs in Slovenia.Harm reduction journal · 2025Article
- Long-term outcome in people who use drugs successfully treated for hepatitis C infection with glecaprevir/pibrentasvir.Journal of virus eradication · 2024Article
- Rate of hepatitis C reinfection after successful direct-acting antivirals treatment among people who inject drugs in Spain: the LIVERate study.BMC public health · 2024Observational
- Sustained Long-Term Decline in Anti-HCV Neutralizing Antibodies in HIV/HCV-Coinfected Patients Five Years after HCV Therapy: A Retrospective Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Bridging the gap: Addressing disparities in hepatitis C screening, access to care, and treatment outcomes.World journal of hepatology · 2024Review
- Update on Hepatitis C Vaccine: Results and Challenges.Viruses · 2024Review
- Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment.Life (Basel, Switzerland) · 2023Review
- First Do No Harm? Modeling Risks and Benefits of Challenge Trials for Hepatitis C Vaccine Development.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Shorter Duration Hepatitis C Virus Treatment is Associated with Better Persistence to Prescription Refills in People Who Inject Drugs: A Real-World Study.Advances in therapy · 2023Article
- Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study.Canadian liver journal · 2023Article
- Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs.American journal of preventive medicine · 2023Article
- World Hepatitis Day 2023: Are we close to the target?The Indian journal of medical research · 2023Article
- HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates.JHEP reports : innovation in hepatology · 2022Article
- Country versus pharmaceutical company interests for hepatitis C treatment.Health care management science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The availability of effective, simple, well-tolerated oral direct-acting antiviral (DAA) hepatitis C regimens has raised optimism for hepatitis C virus (HCV) elimination at the population level. HCV reinfection in key populations such as people who inject drugs (PWID) and HIV-infected men who have sex with men (MSM) however threatens the achievement of this goal from a patient, provider and population perspective. The goal of this review was to synthesize our current understanding of estimated rates and factors associated with HCV reinfection. This review also proposes interventions to aid understanding of and reduce hepatitis C reinfection among PWID and HIV-infected MSM in the oral direct-acting antiviral era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.